NEFL and amyotrophic lateral sclerosis: However, a recent study reveals that riluzole does not reduce serum NfL levels in ALS patients [67], calling into question either the ability of riluzole to slow neurodegeneration or the utility of NfL as a reliable biomarker to track responses to therapy.